 NEW YORK, Aug. 04, 2021 GLOBE NEWSWIRE -- BeyondSpring the Company or BeyondSpring NASDAQ: BYSI, a global pharmaceutical company focused on the development of cancer therapeutics, announced today the positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC EGFR wild type compared to docetaxel alone n559. Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent SIMBA, which is a potent antigen presenting cell APC inducer. The data released today showed that compared to docetaxel alone, the combination met the primary endpoint of increasing overall survival mean OS, p 0.03; OS log rank, p 